Ovidiu Chioncel

List of Publications by Citations

Source: https://exaly.com/author-pdf/9775231/ovidiu-chioncel-publications-by-citations.pdf

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132 20,660 41 143 g-index

papers 30,747 8 5.97 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
132	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of	9.5	7751
131	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
130	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
129	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
128	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
127	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
126	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013 , 15, 808-17	12.3	462
125	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
124	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 1173-84	12.3	388
123	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020 , 41, 12-85	9.5	330
122	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 1169-1186	12.3	325
121	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016 , 18, 613-25	12.3	316
120	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1574-1585	12.3	301
119	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 226-41	12.3	292
118	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010 , 12, 1076-84	12.3	258
117	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
116	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204

(2018-2019)

115	EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. <i>European Heart Journal</i> , 2019 , 40, 3222-3232	9.5	169
114	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1242-1254	12.3	166
113	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure,	12.3	147
112	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with	12.3	127
111	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 553-576	12.3	118
110	Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2276-85	15.1	113
109	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019 , 21, 827-843	12.3	107
108	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017 , 390, 1737-1746	40	106
107	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 54-65	12.3	92
106	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 196-213	12.3	85
105	Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1315-1341	12.3	83
104	Utilization of levosimendan in the cardiac ICU: case series. <i>Critical Care</i> , 2009 , 13, P168	10.8	78
103	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of	12.3	74
102	Acute heart failure congestion and perfusion status Himpact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352	12.3	62
101	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure,	12.3	61
100	2020 , 22, 1966-1983 Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. <i>PLoS ONE</i> , 2012 , 7, e36284	3.7	60
99	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1495-1503	12.3	56
98	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018 , 6, 452-462	7.9	51

97	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association	12.3	50
96	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. European Journal of Heart Failure, 2018, 20, 332-341	12.3	49
95	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9	49
94	The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. <i>American Heart Journal</i> , 2011 , 162, 142-53.e1	4.9	47
93	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1984-1986	12.3	44
92	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
91	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 157-174	12.3	41
90	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart	12.3	40
89	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3	35
88	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 92-102	12.3	35
87	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 2272-2289	12.3	33
86	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019 , 14, 197-214	2.9	33
85	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1378-1389	12.3	32
84	Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. <i>Current Heart Failure Reports</i> , 2014 , 11, 416-27	2.8	30
83	Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. <i>European Journal of Heart Failure</i> , 2020 , 22, 2327-2339	12.3	30
82	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	30
81	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6	3	28
80	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. European Journal of Heart Failure, 2021 , 23, 906-914	12.3	28

(2020-2014)

79	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
78	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314	12.3	23
77	Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. <i>European Journal of Heart Failure</i> , 2019 , 21, 1353-1365	12.3	22
76	Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management. <i>European Journal of Heart Failure</i> , 2015 , 17, 1223-7	12.3	21
75	Natriuretic peptide-guided management in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 556-68	1.9	21
74	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641	12.3	19
73	The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 99-108	4.3	19
72	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 122-129	4.2	18
71	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 281-291	12.3	17
70	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
69	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 315-329	12.3	16
68	The bumpy road to drug development for acute heart failure. <i>European Heart Journal Supplements</i> , 2016 , 18, G19-G32	1.5	16
67	Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. <i>American Journal of Therapeutics</i> , 2008 ,	1	15
66	Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. <i>European Journal of Heart Failure</i> , 2019 , 21, 1231-1244	12.3	14
65	Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 92-104	1.9	14
64	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	14
63	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020 , 22, 638-645	12.3	13
62	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1424-1437	12.3	13

61	Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 2018, 20, 842-850	12.3	13
60	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019 , 21, 1459-1467	12.3	13
59	Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 331-40	1.9	12
58	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy.	12.3	10
57	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015 , 10, e0125164	3.7	9
56	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3	8
55	Therapeutic Advances in the Management of Cardiogenic Shock. <i>American Journal of Therapeutics</i> , 2019 , 26, e234-e247	1	8
54	The Vulnerable Phase of Heart Failure. American Journal of Therapeutics, 2018, 25, e456-e464	1	8
53	Inotropes in acute heart failure. Continuing Cardiology Education, 2017, 3, 107-116		7
52	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology <i>European Journal of Heart Failure</i> , 2022 , 24, 143-168	12.3	7
51	Characteristics of Intensive Care in Patients Hospitalized for Heart Failure in Europe. <i>Heart Failure Clinics</i> , 2015 , 11, 647-56	3.3	6
50	Pulmonary Oedema-Therapeutic Targets. <i>Cardiac Failure Review</i> , 2015 , 1, 38-45	4.2	6
49	Coronary sinus visualization by 3-dimensional real-time echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2008 , 21, 371-6	5.8	6
48	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
47	Pathophysiology of Takotsubo syndrome a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology Part 2: vascular pathophysiology, gender and sex hormones,	12.3	6
46	genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Mega-trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707	12.3	6
45	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018 , 25, e475-e486	1	6
44	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021 , 23, 1597-1609	12.3	6

43	Cardiogenic shock in cancer. Heart Failure Reviews, 2019, 24, 997-1004	5	5
42	The electrocardiographic abnormalities in highly trained athletes compared to the genetic study related to causes of unexpected sudden cardiac death. <i>Journal of Medicine and Life</i> , 2009 , 2, 361-72	1.5	5
41	Left ventricular function monitoring in heart failure. European Heart Journal Supplements, 2019 , 21, M1	7±1.4∱19	5
40	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 597-607	5	4
39	Anterolateral papillary muscle rupture: diagnosis and successful treatment (a case report). <i>Echocardiography</i> , 2002 , 19, 143-4	1.5	4
38	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry European Journal of Heart Failure, 2021,	12.3	4
37	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007347	7.6	4
36	Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?. <i>European Journal of Heart Failure</i> , 2019 , 21, 1398-1401	12.3	3
35	Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study. <i>Clinical Research in Cardiology</i> , 2021 , 110, 993-1005	6.1	3
34	Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 701-6	1.9	3
33	Renal function, electrolytes, and congestion monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019 , 21, M25-M31	1.5	3
32	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. <i>American Journal of Therapeutics</i> , 2019 , 26, e222-e233	1	3
31	The value of a superior vena cava collapsibility index measured with a miniaturized transoesophageal monoplane continuous echocardiography probe to predict fluid responsiveness compared to stroke volume variations in open major vascular surgery: a prospective cohort study. Journal of Clinical Monitoring and Computing, 2020, 34, 491-499	2	3
30	Optimal Endpoints of Acute Heart Failure Therapy. <i>American Journal of Therapeutics</i> , 2018 , 25, e465-e4	7 <u>4</u>	3
29	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021 ,	3.7	3
28	Surgical Management of Type A Acute Aortic Dissection in Patients With Marfan Syndrome: A Single Center Experience. <i>Revista Medico-chirurgicala A Societatii De Medici Si Naturalisti Din Iasi</i> , 2016 , 120, 611-18		3
27	Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role for catecholamines and	12.3	3
26	sympathetic nervous system European Journal of Heart Failure, 2021, Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure Frontiers in Cardiovascular Medicine, 2021, 8, 750965	5.4	2

25	Rare tumors of the heartangiosarcoma, pericardial lipoma, leiomyosarcoma. Three case reports. Journal of Medicine and Life, 2010 , 3, 178-82	1.5	2
24	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
23	Understanding cardiac systolic performance beyond left ventricular ejection fraction 2020 , 1, 75-84		2
22	ST Segment Elevation Myocardial Infarction Due to Severe Ostial Left Main Stem Stenosis in a Patient with Syphilitic Aortitis. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2016 , 54, 74-9	1.5	2
21	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. ESC Heart Failure, 2021,	3.7	2
20	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021,	3.7	2
19	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 487-496	4.3	2
18	Resuscitation of sudden cardiac death caused by acute epileptic seizures: A case report. <i>Journal of Acute Disease</i> , 2016 , 5, 168-171	0.9	1
17	"Dynamic imaging" (systolic compression) of myocardial bridge visualised by electronic beam computed tomography. <i>Heart</i> , 2007 , 93, 1135	5.1	1
16	Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report. <i>Heart Surgery Forum</i> , 2019 , 22, E340-E342	0.7	1
15	Transseptal Approach for Mitral Valve Replacement in Dextrocardia with Situs Inversus Totalis: A Case Report and Review of the Literature. <i>Heart Surgery Forum</i> , 2020 , 23, E030-E033	0.7	1
14	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). <i>Romanian Journal of Laboratory Medicine</i> , 2018 , 26, 271-281	0.3	1
13	Microcirculatory Dysfunction in Acute Heart Failure 2020 , 193-221		О
12	Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply. <i>European Journal of Heart Failure</i> , 2021 , 23, 197-198	12.3	O
11	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. <i>European Journal of Internal Medicine</i> , 2021 , 94, 73-84	3.9	О
10	Amended STRONG-HF study design. European Journal of Heart Failure, 2021 , 23, 1981-1982	12.3	O
9	Percutaneous Closure of Gerbode Defect Type II Post-TAVR With Amplatzer Muscular VSD Occluder. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, e229-e230	5	О
8	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021 , 240, 73-80	4.9	O

LIST OF PUBLICATIONS

7	Rare Cause of Severe Mitral Regurgitation after TAVI: Case Report and Literature Review <i>Medicina</i> (<i>Lithuania</i>), 2022 , 58,	3.1	О
6	Successful concomitant open surgical repair of aortic arch pseudoaneurysm and percutaneous myocardial revascularization in a high risk patient: A case report. <i>International Journal of Surgery Case Reports</i> , 2020 , 74, 86-90	0.8	
5	Successful Management of Unremitting Spasm after Myocardial Revascularization Exclusively with Bilateral Internal Thoracic Arteries in Y-graft Configuration: A Case Report. <i>Heart Surgery Forum</i> , 2019 , 22, E283-E286	0.7	
4	An unusual association: right atrial myxoma and severe left ventricular dysfunction. Case report and review of the literature. <i>Heart Surgery Forum</i> , 2014 , 17, E285-7	0.7	
3	Echocardiographic Hemodynamic Heterogeneity of Advanced Heart Failure Patients as Compared to Patients with P re-Heart Failure (Revista Romana De Cardiologie, 2021 , 31, 351-359	0.1	
2	Mihai Gheorghiade, MD-Life and Concepts. <i>American Journal of Therapeutics</i> , 2018 , 25, e453-e455	1	

Recurrent atrial myxoma. *Romanian Journal of Internal Medicine*, **2004**, 42, 625-34